Definition
History
In 1948, Isaac Michaelson posited that a diffusible, hypoxia-induced “factor X” was released by nonperfused retina and caused angiogenesis. Judah Folkman later studied tumor vasculature and hypothesized that tumors secrete a diffusible, angiogenic growth factor which he termed “tumor angiogenesis factor (TAF).” He also suspected TAF was important in ocular neovascularization and theorized that angiogenesis inhibitors could be used to treat cancer and other angiogenesis-dependent diseases. In the 1980s, two groups separately described what we now know as vascular endothelial growth factor (VEGF). Dvorak and Senger described an inducer of vascular leakage and vascular permeability factor (VPF), and Napoleone Ferrara identified angiogenic VEGF. It was not until 1993, however, that Ferrara created an antibody against VEGF and proved...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Das A, Friberg TR (eds) (2011) Therapy for ocular angiogenesis: principles and practice. Wolters Kluwer Health/Lippincott Williams and Wilkins, Philadelphia
Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 27:787–794
Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS (2006) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113:2002–2011
Nguyen QD, Rodrigues EB, Farah ME, Mieler WF (eds) (2010) Retinal pharmacotherapy. Saunders/Elsevier, Maryland Heights
Van der Reis MI, La Heij EC, De Jong-Hesse Y et al (2011) A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 31:1449–1469
Ventrice P, Leporini C, Aloe JF et al (2013) Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother 4:S38–S42
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer-Verlag GmbH Germany
About this entry
Cite this entry
Liang, M.C., Heier, J.S. (2018). Antivascular Endothelial Growth Factor. In: Schmidt-Erfurth, U., Kohnen, T. (eds) Encyclopedia of Ophthalmology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69000-9_1091
Download citation
DOI: https://doi.org/10.1007/978-3-540-69000-9_1091
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-68292-9
Online ISBN: 978-3-540-69000-9
eBook Packages: MedicineReference Module Medicine